MTOR and melanoma: TMZ; rapamycin (RAP), a selective mammalian target of rapamycin (mTOR) inhibitor; and bevacizumab (BVZ), a humanized anti-VEGF monoclonal antibody, were co-loaded in Intralipid® and tested in vivo on the B16-F10 melanoma mouse model.